生物活性 | |||
---|---|---|---|
描述 | Rosiglitazone maleate, a potent and selective activator of PPARγ, exhibits EC50 values of 30 nM and 100 nM for PPARγ1 and PPARγ2, respectively, and a Kd of approximately 40 nM for PPARγ. Rosiglitazone (BRL49653) at concentrations of 0.1, 1, 10 μM, promotes the differentiation of C3H10T1/2 stem cells into adipocytes[1]. Rosiglitazone activates PPARγ with an EC50 of 60 nM[2]. Rosiglitazone (1 μM) activates PPARγ, which binds to the NF-α1 promoter, enhancing gene transcription in neurons. Additionally, Rosiglitazone (1 μM) protects Neuro2A cells and hippocampal neurons against oxidative stress and upregulates BCL-2 expression in an NF-α1-dependent manner[3]. Rosiglitazone effectively blocks TRPM3 channels with IC50 values of 9.5 μM and 4.6 μM against nifedipine- and PregS-evoked activities, respectively, through mechanisms not involving PPARγ. It also inhibits TRPM2 channels at a higher concentration, with an IC50 of approximately 22.5 μM. Additionally, Rosiglitazone acts as a potent activator of TRPC5 channels, with an EC50 of about 30 μM[4]. |
细胞研究 | |||||
---|---|---|---|---|---|
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
HepG2 cells | Function assay | Peroxisome proliferator activated receptor gamma agonistic activity in HepG2 cells, EC50=0.73 μM | 10714503 |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00306696 | Diabetes Mellitus | Phase 4 | Completed | - | - |
NCT00367055 | Type 2 Diabetes Mellitus | Phase 4 | Completed | - | - |
NCT00367055 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.11mL 0.42mL 0.21mL |
10.56mL 2.11mL 1.06mL |
21.12mL 4.22mL 2.11mL |
参考文献 |
---|